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Abstract: Aims. Depression has been identified as a risk factor for an adverse prognosis and
reduced survival in patients with acute coronary syndrome (ACS). The number of
endothelial progenitor cells (EPCs) is an independent predictor of clinical outcomes in
patients with ACS. The aim was to evaluate the impact of depression on EPC levels in
patients with ACS.
Methods. Out of 74 ACS patients (23 non-ST-segment elevation myocardial infarction
(NSTEMI), 48 STEMI), 36 had a diagnosis of major depressive episode (MDE)
according to DSM-IV criteria at the time of the inclusion in the study. Control groups
were: 15 healthy subjects and 18 patients with current MDE without a history of
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
cardiovascular diseases. EPCs were defined as CD34+CD133+KDR+ and evaluated
by flow cytometry. All patients underwent standardized cardiological and
psychopathological evaluations. Parametric and non-parametric statistical tests were
performed where appropriate.
Results. ACS patients with MDE showed a significant decrease in circulating EPC
number compared to ACS patients without MDE (P<0.001). The ACS study population
was then subdivided into STEMI and NSTEMI groups, and inside each group again
patients with MDE showed a significant decrease in circulating CD34+CD133+KDR+
EPCs compared to others (P<0.001).
Conclusions. We showed that ACS patients with MDE have a reduced number of
circulating CD34+CD133+KDR+ cells compared to ACS patient without MDE,
suggesting that the presence of MDE reduce the response of bone-marrow to acute
ischemic events. Considering the reparative role of EPCs in ACS patients, we suppose
that patients with MDE might be protected less than patients without MDE.
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Introduction  
There is increasing knowledge regarding comorbidity between depression and 
cardiovascular disease, which are the most common disorders in developed countries 
1-
3
;  indeed major depression is associated with a fourfold increase in the risk of mortality 
during the first 6 months after acute coronary syndrome (ACS), although the 
mechanisms underlying this association are still not clear  
4-6
. Inflammation, for 
example, has been involved as a  biological mechanism common to depression and 
ischemic heart disease and increased levels of inflammatory markers have been well 
documented in depression 
7
. On the other hand, inflammation is thought to be involved 
in all stages of atherosclerosis 
8
, but the biological mechanisms by which inflammation 
can mediate the relationship between depression and increased risk of cardiovascular 
events have not been clarified so far. 
Recently, it has been explored the effect of depressive disorder on bone marrow-derived 
cells described in 1997 by Asahara et al. 
9
. Although a unifying definition regarding the 
characterization of endothelial progenitor cells (EPCs) does not exist, most researcher 
identify EPCs as CD34+CD133+KDR+  positive cells 
10
. EPCs have the ability to 
influence adult vasculogenesis in areas with reduced oxygen supply or by stimulating 
the re-endothelialization of injured blood vessels 
11-14
. A reduction in the levels of EPCs 
has also predictive value in progression of atherosclerotic disease, supporting the 
important role that endogenous vascular repair plays in modulating the clinical outcome 
of coronary artery disease (CAD) 
15
.  
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The relation between EPCs and cardiovascular risk factors has also been extensively 
investigated 
15-18
 and several studies  gave to the number of EPCs the role of new 
biomarker of prognostic value, resulting independent predictor of clinical outcomes in 
patients with CAD 
15, 19
.  
EPCs also appear to play an important role in the molecular background of depression-
associated cardiovascular morbidity. Indeed, recent studies showed a decreased number 
of circulating EPCs in patients with depression compared to healthy subjects. This 
reduction was observed to be inversely proportional to the severity of depressive 
disorder and the level of tumour necrosis factor alpha (TNF-a) 
20-21
. 
Up to now, there are no data on the relationship between circulating EPCs, depression 
and ACS. The objective of the present study, therefore, has been to evaluate the number 
of circulating EPCs in ACS patient with or without major depressive episodes (MDE), 
compared with healthy subjects and patients with current MDE without a history of 
cardiovascular diseases. 
 
Methods 
Subjects 
The study population consisted of non-consecutive 74 ACS patients (55 males and 19 
females, mean age 58±10 years) who were admitted to the Intensive Care Units of three 
Cardiology Units (La Spezia, Sarzana and Lucca) serving the same catchment area. 
Patients were admitted if they met the criteria for ACS, either acute myocardial infarct 
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with or without ST-segment elevation (STEMI and NSTEMI, respectively) or unstable 
angina (UA), verified by standard ACS criteria 
22
.  
Exclusion criteria were age > 79 years, neoplastic disease, severe pulmonary, hepatic or 
renal insufficiency, infections requiring antibiotics, autoimmune disease, 
immunosuppressive therapy, severe anaemia and severe degenerative disease of the 
central nervous system. 
Control groups included: 18 psychiatric patients  with current MDE without 
cardiovascular disorders, enrolled from the Department of Psychiatry of the University 
of Pisa and 15 healthy volunteers ascertained from personnel working at the 
Cardiothoracic and Vascular Department of University of Pisa, evaluated by the 
Structured Clinical Interview for Psychiatric Disorders (SCID-I) 
23
, to determine the 
presence of Axis I psychiatric disorders according to DSM-IV criteria. Both control 
groups were matched for gender, age, and smoking status with ACS patients sample. 
Exclusion criteria were the same as those for ACS patients. The study was conducted in 
accordance with the Declaration of Helsinki, was approved by the local ethics 
committees and written informed consent was obtained from all patients (or their 
guardians).  
The study complied with the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) recommendations 
24
. 
 
Study design 
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Complete cardiological clinical assessment and related haematological tests were 
performed at the time of enrolment (hospital admission for ACS event).  
Psychiatric evaluations were performed as soon as patient’s clinical condition allowed 
them, within three/four days following admission. 
Blood samples collection for EPC evaluation were carried out after three/four days from 
ACS event. This timing was established on the basis of previous data documenting an 
effect of the acute phase on EPC’s number 25. 
Cardiovascular risk factors, including tobacco smoking, diabetes mellitus, 
hypercholesterolemia, and hypertension, were determined at the time of blood 
collection. The body height and weight, blood pressure, and body mass index (BMI) of 
all subjects were measured. Hypertension was defined as either resting systolic or 
diastolic blood pressure ≥ 140/90mmHg at two different times or on medications. 
Diabetes mellitus was defined as a serum fasting glucose of  ≥ 7.1 mmol/l or on 
medications. Hypercholesterolemia was defined as a fasting total serum cholesterol 
level of  ≥ 4.9 mmol/l or on medications. Smoking status was recorded as current 
smoker or past smoker. Based on the observation of Kondo et al. 
26
 on the effects of 
smoking cessation on EPC levels, ex-smokers were defined as those who had quit 
smoking at least 1 month before the cardiovascular events. Fasting blood samples were 
obtained from all subjects to determine serum creatinine, glucose, C-reactive protein 
(CRP) level and lipid levels.  
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Cardiological evaluation  
Data on patients’ demographics, medical history, clinical characteristics, 
electrocardiographic findings, ACS definition and treatment interventions, as well as in-
hospital outcomes were reported in a detailed standardized case record form, adapted 
from the Blitz Study 
27
, by a trained cardiologist. The details on symptoms onset, first 
medical help seeking and arrival at hospital were collected as soon as patients could be 
interviewed. Particular care was taken in assessing the timing of hospital arrival, ECG 
execution, and reperfusion treatment. Additional items included length of stay in the 
CCU and overall hospital stay, timing of invasive procedures and transfer to a tertiary 
care hospital to undergo coronary angiography and/or revascularization. 
 
Psychiatric Assessment 
All patients were evaluated by the SCID-I 
23
 to determine the presence of Axis I 
psychiatric disorders according to DSM-IV criteria. The presence and severity of 
depression was assessed by the 17-Item Hamilton Depression Rating Scale (HDRS) 
28
. 
The Hamilton Depression (HAM-D) Rating Scale provides an indication of depression 
and, over time, a guide to recovery. It is one of the most widely used and accepted 
outcome measures for evaluating the severity of depression symptoms. The HAM-D 
was administered by a trained psychiatrist or psychologist, blind to psychiatric MDE 
diagnosis, using a semi-structured interview. Eight items are scored on a 5-point scale, 
ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Based on the 
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HDRS-17 scale, the American College of Neuropsychopharmacology (ACNP) 
recommended using scores of ≤ 5 to define the absence of clinically relevant depression 
29
. Scores between 6 and 13 indicate mild depression, from 14 to 18 moderate 
depression, from 19 to above severe depression.  
 
Evaluation of circulating endothelial progenitor cells 
The circulating EPCs were measured after 3-4 day of ACS event and defined by the 
expression of surface markers CD34/KDR/CD133 by flow cytometric analysis 
30-31
. 
EDTA-peripheral blood samples were processed within 4 h after collection. Briefly, 100 
µl of samples of peripheral venous blood of controls and ACS patients were incubated 
with PerCP-conjugated monoclonal antibodies anti human CD34, AlexaFluor 647- 
conjugated anti KDR and PE- conjugated anti CD133 (Miltenyi Biotec, Bergisch 
Gladbach, Germany) in the dark at 4°C, according to manufacturers’ instruction. Red 
cells were lysed with 1x BD FACS Lysis solution (BD Pharmigen, UK) and incubated 
for 5 minutes at room temperature. A PE isotype-matched antibody were used as 
negative control. 
Validation of the assay was performed adopting the gating strategy defined by the 
International Society of Haematotherapy and Graft Engineering (ISHAGE) guidelines 
32
. Quantitative fluorescence analysis were performed with a FACS-Calibur instrument 
and data were processed using Cell Quest Software (BD Pharmigen, UK). Each analysis 
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included at least 500,000 events. The number of EPCs was expressed as absolute 
number of cells per ml of blood. 
 
Statistical analysis 
Continuous data were expressed as mean ± SD. The normality of distributions of EPC 
numbers was assessed using a one-sample Kolmogorov-Smirnov test. As EPCs resulted 
non-normal distributed data were log-transformed, and after normalization, comparisons 
between more than two groups were performed by one-way ANOVA. Continuous 
variables were compared with Student’s t-test or Mann–Whitney U-test, as appropriate. 
Categorical data were compared using Fishers’ exact probability or χ2-test, as 
appropriate. In addition, McNemar’s tests were performed in 2x2 contingency tables for 
matched pairs of subjects to evaluate marginal homogeneity. The Spearman's test was 
used to identify significant correlations between two numerical variables. Statistical 
significance was taken at the two-tailed p<0.05 level. All analyses were performed 
using the Statistical Package for Social Sciences (SPSS) version 20 (SPSS, Chicago, IL, 
USA).  
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Results 
Baseline Characteristics 
The 74 (55 males and 19 females) adult ACS patients were sub-typed as follows: n=48 
STEMI (age 58±11 years); n=23 NSTEMI (age 60±7 years); n=3 UA (age 62±13 
years). Patients’ characteristics at baseline, including clinical risk factors and therapy, 
are summarized in Table 1. 
There were no significant differences in age, gender and prevalence of risk factors 
between the ACS patients with or without MDE (Table 1; all P>0.05). Furthermore, 
there were no significant differences in BMI, serum total cholesterol, low and high 
density lipoprotein and triglycerides, creatinine, CRP, and fasting blood sugar levels 
between the two groups (all P>0.05; table 1). 
 
Evaluation of depression in ACS patient  
Of  74 ACS patients, 36 (n=22 STEMI, age 57± 12 years; n=12 NSTEMI, age 61±6 
years; n=2 UA, age 69±1 years) resulted to have a MDE according to the SCID-I. The 
36 ACS patients with MDE reported a mean HDRS total score of  7.9 ± 5. Demographic 
and clinical characteristics, including laboratory tests and cardiovascular risk factors, of 
ACS patient with or without MDE, are summarized in Table 1. 
 
EPC levels in peripheral blood samples of patients with ACS  
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As shown in Figure 1, ACS patients with MDE (ACS + MDE) had a significant 
decrease of circulating CD34+CD133+KDR+ EPC levels compared to ACS patients 
without MDE (ACS) (P<0.001). Moreover, EPC levels was significantly reduced in 
patients with current MDE without a history of cardiovascular disease, here defined as 
cDE (psychiatric controls) compared to healthy subjects (P<0.001). Finally, EPC levels 
was significantly reduced in ACS patients without MDE (ACS) compared to healthy 
subjects (Ctr) (P<0.05).  
The change in EPC numbers correlated negatively with HDRS in patients with ACS (r = 
- 0.34, P= 0.0028) (Figure 2). 
 
EPC levels  in STEMI and NSTEMI patients 
The study population was then analyzed according to STEMI and NSTEMI groups. As 
show in Figure 3(A), STEMI patients with MDE (STEMI + MDE) showed a significant 
decrease in circulating CD133+CD34+KDR+ EPC numbers compared to patients 
without MDE (STEMI) (P<0.001). Again, CD133+CD34+KDR+ EPC levels were 
reduced in STEMI patients without MDE (STEMI) compared to healthy subjects (Ctr) 
(P<0.05) and between healthy subjects and cDE (P<0.001). 
Figure 3 (B) shows log transformed value of CD133+CD34+KDR+  EPC numbers in 
NSTEMI patients. NSTEMI patients with MDE showed a significant decrease in 
CD133+CD34+KDR+  cell numbers compared to NSTEMI patients without MDE 
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(P<0.05). However, in this group there was no significant difference in EPC levels 
between NSTEMI patients without MDE and healthy subjects (P>0.05). 
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Discussion 
Several clinical studies have shown that the number of circulating EPCs is inversely 
proportional to risk factors for atherosclerosis, endothelial dysfunction and future 
cardiovascular events 
15, 18
.  Dome et al., as well as Yang et al., have indicated that EPC 
counts are decreased in patients without specific cardiovascular risk factors with a 
current episode of depression 
20, 33
. Moreover, Friedrich et al. 
34
, reported that 
CD133+CD34+KDR+ cells (which have a frequency in peripheral blood similar to 
CD34+KDR+ cells) are more vasoregenerative and represent a more immature EPC 
phenotype, which further matures into endothelial cells. On these assumptions, we 
explored the level of circulating CD133+CD34+KDR+ EPCs in patients with recent 
ACS with concomitant clinically depression as compared to those without. Our data 
showed that the presence of depression was associated with a significantly impaired 
release of circulating CD133+CD34+KDR+ cells in ACS patients (P<0.001).  
It seems worth to emphasize that there were no significant differences in age, gender 
and prevalence of risk factors between the ACS patients with or without depression. 
Furthermore, there were no significant differences in BMI, serum total cholesterol, low 
and high-density lipoprotein and triglycerides, creatinine, CRP, and fasting blood sugar 
levels between the two groups. Several studies reported that in ACS patients, there 
seems to be a trend toward an elevated level of EPCs, suggesting that these cells are 
possibly mobilized in an attempt to participate in vessel repair after severe ischemia 
25, 
35-36
. According to Grundmann et al. 
37
, cell count increases after 3-4 day of an ACS 
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event, however we observed that the number of cells does not reach the value observed 
in healthy volunteers. The increased CD133+CD34+KDR+ cell levels in ACS patients 
may be due to the mobilization of cells from bone-marrow caused by acute vascular 
injury. 
We also found that cells were significantly reduced in ACS patients with current MDE 
compared to ACS patients without MDE (P<0.001). Moreover, according to data 
obtained by Dome et al. 
20
, we found that  cells were significantly reduced in psychiatric 
controls compared to healthy subjects (P<0.001). These data indicate that depression 
itself, independently of its association with an acute coronary syndrome, has an impact 
on circulating EPCs. In fact, the evaluation of severity of depression by HDRS 
embraces a period of time extended from a week preceding the acute cardiac event to 
the moment of evaluation. Baseline psychiatric evaluation occurred within the first three 
days from admission; therefore, it is more likely that the cardiac event, rather than acute 
setting per se, had a relationship with onset of depression. The causal relationships 
between these two phenomena are far from being clear. Dome et al. 
20
 have 
hypothesized a relationship with chronic inflammation processes. These authors, in fact, 
found a decreased level of circulating EPCs in patients with a current episode of 
depression and a significantly elevated TNF-a concentration. Moreover, they observed a 
significant inverse correlation between TNF-a and EPC levels. 
Finally, we observed a significant decrease of CD133+CD34+KDR+ EPC levels in 
patients with MDE compared to ACS patients without MDE, independently on whether 
 14 
they had a STEMI or a NSTEMI. However, no significant differences in cell levels were 
observed between the NSTEMI subgroup without concomitant MDE and healthy 
subjects (P > 0.05). These data corroborate the notion that the recruitment of progenitor 
cells is related to the duration of ischemia rather than to the size of the ischemic 
myocardial area 
38
. 
Limitations 
Some limitations of our study must be acknowledged. First, the relatively small number 
of patients enrolled may limit generalizability of our results. Second, NSTEMI patients 
were relatively underrepresented in our sample due to the exclusion criteria of 80 years.  
Conclusions 
This is the first study, to the best of our knowledge, showing that ACS patients (both 
STEMI and NSTEMI) with concomitant clinically relevant depressive symptoms have a 
reduced level of circulating CD133+CD34+KDR+  EPCs. These data suggest that the 
presence of depression affects bone-marrow response to acute ischemic event. 
Considering the reparative role of EPCs in ACS patients, it can be hypothesized that 
ACS patients who are also depressed may be less protected than patients without MDE 
from the risk of occurrence of new major cardiac events. Notwithstanding, prospective 
studies are needed to confirm this hypothesis. From such a viewpoint, we are 
conducting a prospective study to explore the strength of association between presence 
of depression,  EPC levels and cardiac outcome in patients with ACS. 
 15 
 Finally, our study suggests that individuals with cardiovascular risk factors or with 
definite cardiovascular diseases, such as ACS, should be screened for depression.  
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Figure legends  
Figure 1. EPC levels in ACS patients. CD133+CD34+KDR+  EPCs levels are expressed as 
box plots displaying medians (lines), interquartile range (boxes) and maximum and minimum 
values (whiskers), of log transformed data. STEMI and NSTEMI ACS patients with major 
depressive episode (ACS+MDE) (n=36) show a reduced level of circulating EPCs compared 
with STEMI and NSTEMI ACS patients without MDE (ACS) (n=38), ***P<0.001. 
Moreover, psychiatric controls (cDE) (n=18) show a reduced EPC levels compared with 
healthy subjects (Ctr) (n=15), ***P<0.001. Change in the groups were compared using one-
way ANOVA and Newman-Keuls multiple comparison post-hoc test (p<0.05). 
 
Figure 2. Relationship between progenitor cell levels (EPCs) and  Hamilton Depression 
Rating Scale (HDRS) in ACS patients. (r = - 0.34, P<0.005) 
 
Figure 3. EPC levels in STEMI (A) and in NSTEMI (B) patients. CD133+CD34+KDR+  
EPCs levels are expressed as box plots displaying medians (lines), interquartile range (boxes) 
and maximum and minimum values (whiskers) of log transformed data. STEMI patients (A) 
with major depressive episode (STEMI +MDE) (n=23) show a reduced level of circulating 
EPCs compared with STEMI patient without MDE (STEMI) (n=25), ***P<0.001. NSTEMI 
patients (B) with MDE (NSTEMI +MDE) (n=12) show a reduced EPC levels compared with 
NSTEMI patient without MDE (NSTEMI) (n=14), *P<0.05. Change in the groups were 
compared using one-way ANOVA and Newman-Keuls multiple comparison post-hoc test (p 
<0.05). 
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Table 1. Patients’ baseline characteristics 
 
Ctr 
(n=15) 
cDE  
(n=18) 
ACS 
(n= 38) 
ACS + MDE 
(n=36) 
P-value
#
 
Age (years, mean ± SD) 49 ±12 50 ± 10 58 ± 11 59 ± 10 0.79* 
Gender (male/female) 10/5 11/7 28/10 (74 vs 26 %) 27/9 (75 vs 25 %) 0.79† 
STEMI, n (%) NA NA 26 (68 %) 22 (61 %) 0.80† 
NSTEMI, n (%) NA NA 11 (29 %) 12 (33 %) 0.80† 
UA, n (%) NA NA   1 (2.6 %)   2 (5.5 %) 0.80† 
Cardiovascular Risk Factors 
CAD familiarity, n (%) 5 (33 %) 2 (11 %) 18 (47.4 %) 9 (25 %) 0.06† 
Diabetes, n (%)  3 (20 %) 0 9 (23.7 %) 4 (11 %) 0.22† 
Hypertension, n (%) 6 (40 %) 4 (22 %) 22 (57.9 %) 16 (44.4 %) 0.35† 
Dyslipidemia, n (%)  1 (7 %) 4 (22 %) 19 (50 %) 20 (55.6 %) 0.65† 
Active smokers, n (%)  5 (33 %) 6 (33 %) 15 (39.5 %) 15 (41.7 %) 0.40‡ 
Biochemical parameters 
BMI (Kg/m
2
) 23 ± 4 22 ± 5 24 ± 5 23 ± 5 0.97 § 
Fasting glucose (mg/dl) 86 (78-90) 82 (70-89) 103.5 (91-120) 106 (89-118) 0.85 § 
Total cholesterol (mg/dl)  183 (145-195) 186 (161-202) 190 (161.7-218.7) 198 (162.7-225.7) 0.71 § 
LDL cholesterol (mg/dl)  107 (96.5-118) 111 (105-121) 107 (94.5-120) 129.5 (88-139.2) 0.23 § 
HDL cholesterol (mg/dl)  50 (40-66) 49 (40-56) 43 (35-51) 41.5 (39-47.5) 0.73 § 
Triglycerides (mg/dl)  70 (58-99) 88 (85-117) 134.5 (94-190.2) 124 (94-163) 0.49 § 
C-reactive protein (mg/l) NA NA 0.73 (0.31-1.69) 0.68 (0.25-0.95) 0.60 § 
Creatinine (mg/dl)  0.99 (0.86-1.1) 0.82 (0.54-1.1) 0.92 (0.77-1.12) 0.93 (0.79-1.07) 0.76 § 
Peak-hsTn (ng/ml) NA NA 6.65 (1.05-28) 5.13 (0.62-46.6) 0.64 § 
Therapy at the day of EPC analysis 
Statins, n (%)  NA NA 35 (92 %) 36 (100 %) 0.11† 
ACE inhibitors, n (%)  NA NA 5 (13 %) 4 (11 %) 0.71† 
Beta-blockers, n (%)  NA NA 34 (89 %) 34 (94 %) >0.99† 
Oral antidiabetics, n (%) NA NA 2 (5 %) 1 (3 %) 0.49† 
Nitrates, n (%) NA NA 4 (11 %) 2 (5 %) 0.67† 
Insulin, n (%) NA NA 5 (13 %) 3 (8 %) 0.71† 
Diuretics, n (%) NA NA 7 (18 %) 7 (19 %) >0.99† 
Antiplatelet agents,n (%) NA NA 36 (95 %) 36 (100 %) >0.99† 
Anticoagulants, n (%) NA NA 7 (18 %) 6 (17 %) 0.768† 
*Independent-sample t-test. †Fischer’s exact test. ‡Mc Nemar test. §Mann–Whitney U-test. ACS, acute coronary 
syndrome; MDE, major depressive episode; CAD, coronary artery disease; BMI, body mass index; LDL, low density 
lipoprotein; HDL, high density lipoprotein; hsTn, high sensitive troponine. Data are expressed as number (n), 
percentage (%) and as median and IQR.. 
# 
Difference between ACS vs ACS+MDE patients.
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